Biologics in inflammatory disease: Infliximab associated risk of lymphoma development [9]

Gut

Volumn 54, Issue 5, 2005, Pages 732-733

  Bucher, C ^a   Degen, L ^a   Dirnhofer, S ^b   Pless, M ^a   Herrmann, R ^a   Schraml, P ^b   Went, P ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD30 ANTIGEN; INFLIXIMAB;

ADULT; CANCER RISK; CASE REPORT; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; LETTER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PHENOTYPE; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17644366511     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.059352     Document Type: Letter

References (9)

1. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
2. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment end lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7.
3. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remiss on in Crohn's disease. Gastroenterology 1999;117:761-9.
4. Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 2002;41:1194-5.
5. Mahe E, Descamps V, Grossin M, et al. CD30- T-cell lymphoma in a patient with psoriasis treaed with ciclosparin and infliximab. Br J Dermatol 2003;149:170-3.
6. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
7. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
8. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial: Lancet 2002;359:1541-9.